ArticleCurrent oncology (Toronto, Ont.)2023
The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Patients with Metastatic Renal Cell Carcinoma.
Article in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- The prognostic impact of systemic inflammation and nutritional indicators on targeted therapy for renal cell carcinoma: a systematic review and meta-analysis.Frontiers in nutrition · 2026Pooled it
- Preoperative C-reactive protein-to-albumin ratio as a prognostic marker of histopathological characteristics and survival outcomes following radical cystectomy.Frontiers in oncology · 2026Article
- Evaluating the prognostic role of glucose-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in first line: a study by the Turkish Oncology Group Kidney Cancer Consortium (TKCC).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Evaluating the Inflammatory Protein Ratio (IPR) as an Inflammation-Based Biomarker for Cancer Diagnosis.International journal of molecular sciences · 2025Article
- Prognostic value of the neutrophil‑to‑lymphocyte ratio in renal cell carcinoma: A systematic review and meta‑analysis.Oncology letters · 2025Article
- Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols.Journal for immunotherapy of cancer · 2025Article
- Neutrophil to lymphocyte ratio and tumour burden for treatment efficacy stratification in renal cell carcinoma patients receiving nivolumab plus ipilimumab.ESMO real world data and digital oncology · 2025Article
- Blood-derived ratio indexes associated with severity and prognosis of immune checkpoint inhibitor-related cardiotoxicity: a retrospective analysis.Frontiers in oncology · 2025Article
- Optimizing early-phase immunotherapy trials: the role of biomarker enrichment strategies.Frontiers in immunology · 2025Review
- Association of neutrophil to lymphocyte ratio with all-cause and cardiovascular mortality among individuals with kidney stone disease: result from NHANES, 2007-2018.Frontiers in endocrinology · 2025Article
- Paraneoplastic Resolution Holds Prognostic Utility in Patients with Metastatic Renal Cell Carcinoma.Cancers · 2024Article
- Evaluation of prognostic factors for late recurrence in clear cell renal carcinoma: an institutional study.Frontiers in oncology · 2024Article
- Construction of the prognostic model in non-metastatic renal cancer patients with venous tumor thrombus.Translational andrology and urology · 2023Article
- Second-Line Treatment of Metastatic Renal Cell Carcinoma in the Era of Predictive Biomarkers.Diagnostics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetastatic renal cell carcinoma (mRCC) is an aggressive cancer characterised by an increased recurrence rate and an inadequate response to treatment. This study aimed to investigate the importance of the neutrophil-to-lymphocyte ratio (NLR) as a prognostic marker for long-term survival in patients with mRCC.
methodsWe retrospectively analysed data from 74 patients with mRCC treated at our medical centre with tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs). We evaluated the predictive value of NLR for overall survival (OS) in these patients.
resultsThe median OS was 5.1 months in the higher NLR group (≥3) and 13.3 months in the lower NLR group (<3) (
conclusionsThis retrospective study showed that adding NLR to other Memorial Sloan Kettering Cancer Center (MSKCC) and International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) variables might improve the prognostic and predictive power of these models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.